Trial Profile

PAveMenT: Phase Ib Study of Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 30 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avelumab (Primary) ; Palbociclib (Primary)
Indications Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
Focus Adverse reactions; Therapeutic Use
Acronyms PAveMenT

Most Recent Events

03 Nov 2023 Planned End Date changed from 1 Jul 2024 to 31 Dec 2025.
03 Nov 2023 Planned primary completion date changed from 1 Jan 2024 to 31 Jul 2025.
10 Dec 2022 Results (n=14) assessing the dose finding phase Ib cohort A of the PAveMenTtrial combining avelumab and palbociclib presented at the 45th Annual San Antonio Breast Cancer Symposium

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com